search
Back to results

Evaluation of ONCOXIN® in Oral Mucositis, Appetite and Body Mass in Cancer Patients.

Primary Purpose

Mucositis Oral

Status
Completed
Phase
Phase 2
Locations
Russian Federation
Study Type
Interventional
Intervention
Oncoxin®
Sponsored by
Catalysis SL
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional supportive care trial for Mucositis Oral focused on measuring Oral Mucositis, Nutritional supplement, Chemotherapy, Radiotherapy, Ocoxin / Oncoxin

Eligibility Criteria

45 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. A signed and dated informed consent form;
  2. Patients of both genders, aged 45-75;
  3. Malignant neoplasms which have radio-, chemotherapy or their combinations prescribed;
  4. ECOG ≤3;
  5. WHO oral toxicity scale grade 2 - 3.

Exclusion Criteria:

  1. Significant, according to the investigator judgement, concomitant diseases or states which make it complicate or even impossible the patient's participation in the study or make it difficult to interpret the clinical data obtained in any stage of the study always including the following:

    • Mental disorders;
    • Serious/chronic infectious and parasitic diseases;
    • Intolerability to any of ONCOXIN components.
  2. Relations with study center personnel (study center staff or family member of the investigator, coordinator or assistant).
  3. If the patient fails to assess his/her physical and emotional condition;
  4. If the patient fails to comply with the requirements;
  5. Patient's refusal to participate in the study;
  6. Pregnancy or lactation.

Sites / Locations

  • Medical Scientific centre of professor Shumsky

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

No Intervention

Arm Label

Oncoxin®

No Oncoxin Treatment®

Arm Description

Chemo-, radiotherapy or their combination + standard oral mucositis treatment + ONCOXIN

Chemo-, radiotherapy or their combination + standard oral mucositis treatment.

Outcomes

Primary Outcome Measures

Oral mucositis grade in patients during chemotherapy and radiotherapy treatments
Efficacy of OCOXIN on oral mucositis symptoms in patients who receive chemotherapy and/or radiotherapy with WHO oral toxicity scale grades. The WHO scale is dependent on both objective and subjective variables, and measures anatomical, symptomatic as well as functional components of oral mucositis. WHO Oral Mucositis Grading Scale: 0 (none): None I (mild): Oral soreness, erythema II (moderate): Oral erythema, ulcers, solid diet tolerated III (severe): Oral ulcers, liquid diet only IV (life-threatening): Oral alimentation impossible

Secondary Outcome Measures

Nutritional status of the patients during Chemotherapy and radiotherapy treatments related with weight gain
Effects of ONCOXIN on nutritional status in patients who receive chemotherapy and/or radiotherapy measured with body mass measures.
Nutritional status of the patients during Chemotherapy and radiotherapy treatments
Effects of ONCOXIN on nutritional status in patients who receive chemotherapy and/or radiotherapy measured with days with the intake of regular food.
Nutritional status of the patients during Chemotherapy and radiotherapy treatments
Effects of ONCOXIN on nutritional status in patients who receive chemotherapy and/or radiotherapy measured with days with no loss of appetite complaints.

Full Information

First Posted
June 11, 2018
Last Updated
July 31, 2018
Sponsor
Catalysis SL
search

1. Study Identification

Unique Protocol Identification Number
NCT03577535
Brief Title
Evaluation of ONCOXIN® in Oral Mucositis, Appetite and Body Mass in Cancer Patients.
Official Title
Evaluation of ONCOXIN® in Oral Mucositis, Appetite and Body Mass in Cancer Patients. Real World Setting Study.
Study Type
Interventional

2. Study Status

Record Verification Date
June 2018
Overall Recruitment Status
Completed
Study Start Date
November 1, 2017 (Actual)
Primary Completion Date
May 31, 2018 (Actual)
Study Completion Date
July 15, 2018 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Catalysis SL

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Oral mucositis is one of the most spread side effects of anticancer therapy. It is associated with both chemo- and radiotherapy, decreases QoL, relative dose intensity and leads to nutritive deficiency. Oral mucositis causes secondary infections, increased hospital stay, whereas pain syndrome results in an emotional distress, anorexia and disables natural feeding.
Detailed Description
Primary: To evaluate the efficacy of ONCOXIN on oral mucositis symptoms in patients who receive chemotherapy and/or radiotherapy. Secondary: To evaluate the effects of ONCOXIN on nutritional status in patients who receive chemotherapy and/or radiotherapy.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Mucositis Oral
Keywords
Oral Mucositis, Nutritional supplement, Chemotherapy, Radiotherapy, Ocoxin / Oncoxin

7. Study Design

Primary Purpose
Supportive Care
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
15 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Oncoxin®
Arm Type
Experimental
Arm Description
Chemo-, radiotherapy or their combination + standard oral mucositis treatment + ONCOXIN
Arm Title
No Oncoxin Treatment®
Arm Type
No Intervention
Arm Description
Chemo-, radiotherapy or their combination + standard oral mucositis treatment.
Intervention Type
Dietary Supplement
Intervention Name(s)
Oncoxin®
Intervention Description
Chemo-, radiotherapy or their combination + standard oral mucositis treatment + ONCOXIN 25 ml twice daily for 20 days;
Primary Outcome Measure Information:
Title
Oral mucositis grade in patients during chemotherapy and radiotherapy treatments
Description
Efficacy of OCOXIN on oral mucositis symptoms in patients who receive chemotherapy and/or radiotherapy with WHO oral toxicity scale grades. The WHO scale is dependent on both objective and subjective variables, and measures anatomical, symptomatic as well as functional components of oral mucositis. WHO Oral Mucositis Grading Scale: 0 (none): None I (mild): Oral soreness, erythema II (moderate): Oral erythema, ulcers, solid diet tolerated III (severe): Oral ulcers, liquid diet only IV (life-threatening): Oral alimentation impossible
Time Frame
21 days
Secondary Outcome Measure Information:
Title
Nutritional status of the patients during Chemotherapy and radiotherapy treatments related with weight gain
Description
Effects of ONCOXIN on nutritional status in patients who receive chemotherapy and/or radiotherapy measured with body mass measures.
Time Frame
21 days
Title
Nutritional status of the patients during Chemotherapy and radiotherapy treatments
Description
Effects of ONCOXIN on nutritional status in patients who receive chemotherapy and/or radiotherapy measured with days with the intake of regular food.
Time Frame
21 days
Title
Nutritional status of the patients during Chemotherapy and radiotherapy treatments
Description
Effects of ONCOXIN on nutritional status in patients who receive chemotherapy and/or radiotherapy measured with days with no loss of appetite complaints.
Time Frame
21 days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
45 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: A signed and dated informed consent form; Patients of both genders, aged 45-75; Malignant neoplasms which have radio-, chemotherapy or their combinations prescribed; ECOG ≤3; WHO oral toxicity scale grade 2 - 3. Exclusion Criteria: Significant, according to the investigator judgement, concomitant diseases or states which make it complicate or even impossible the patient's participation in the study or make it difficult to interpret the clinical data obtained in any stage of the study always including the following: Mental disorders; Serious/chronic infectious and parasitic diseases; Intolerability to any of ONCOXIN components. Relations with study center personnel (study center staff or family member of the investigator, coordinator or assistant). If the patient fails to assess his/her physical and emotional condition; If the patient fails to comply with the requirements; Patient's refusal to participate in the study; Pregnancy or lactation.
Facility Information:
Facility Name
Medical Scientific centre of professor Shumsky
City
Samara
State/Province
Samara Oblast
ZIP/Postal Code
4433030
Country
Russian Federation

12. IPD Sharing Statement

Plan to Share IPD
Yes

Learn more about this trial

Evaluation of ONCOXIN® in Oral Mucositis, Appetite and Body Mass in Cancer Patients.

We'll reach out to this number within 24 hrs